Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

57
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
57
Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

611
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
611
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

13.4K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Photoaged microplastics disrupt endothelial stretch-sensitive ion channels to impair calcium signaling and vascular integrity.

bioRxiv : the preprint server for biology·2026
Same author

Deciphering sepsis molecular subtypes using large-scale data to identify subtype-specific drug repurposing.

bioRxiv : the preprint server for biology·2026
Same author

Ultrafine particulate matter exposure induces gut microbiota dysbiosis together with ER stress in the liver and worsened atherosclerosis.

Environment international·2025
Same author

Corrigendum to "Subchronic inhalation exposure to ultrafine particulate matter alters the intestinal microbiome in various mouse models" [Environ. Res. 248 (2024) 118242].

Environmental research·2025
Same author

A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular coenzymes Q<sub>9</sub> and Q<sub>10</sub>.

Free radical biology & medicine·2025
Same author

The intestine and cardiovascular disease.

Current opinion in lipidology·2025

Related Experiment Video

Updated: Apr 27, 2026

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
11:57

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions

Published on: April 21, 2016

5.7K

Apolipoprotein A-I mimetics.

Srinivasa T Reddy1, Mohamad Navab, Gattadahalli M Anantharamaiah

  • 1aDepartment of Medicine bDepartment of Obstetrics and Gynecology cDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California dDepartment of Medicine, University of Alabama at Birmingham, Alabama USA.

Current Opinion in Lipidology
|July 1, 2014
PubMed
Summary
This summary is machine-generated.

Apolipoprotein mimetic peptides show promise in treating diseases by reducing inflammatory lipids in the intestine. Novel therapies aim to overcome cost barriers for these potential therapeutic agents.

More Related Videos

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

11.4K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.0K

Related Experiment Videos

Last Updated: Apr 27, 2026

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions
11:57

Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions

Published on: April 21, 2016

5.7K
Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
10:08

Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain

Published on: August 28, 2012

11.4K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Therapeutics

Background:

  • Apolipoprotein mimetic peptides are investigated for therapeutic potential.
  • These peptides mimic high-density lipoprotein (HDL) components.
  • Recent advancements focus on novel therapeutic approaches.

Purpose of the Study:

  • To review recent publications on apolipoprotein mimetics.
  • To summarize their efficacy and therapeutic potential.
  • To highlight emerging strategies in apolipoprotein mimetic therapy.

Main Methods:

  • Literature review of recent publications.
  • Analysis of studies on apolipoprotein mimetic peptides in animal models.
  • Evaluation of novel therapeutic approaches and their challenges.

Main Results:

  • Apolipoprotein mimetics demonstrate efficacy in animal disease models.
  • A key action involves reducing proinflammatory bioactive lipids in the small intestine.
  • High cost, especially for chemically synthesized peptides, is a significant challenge.
  • Emerging novel approaches show promise in overcoming these cost barriers.

Conclusions:

  • Therapies using HDL mimetics and components remain promising despite challenges.
  • Apolipoprotein mimetics offer a potential therapeutic avenue for various diseases.
  • Continued research into cost-effective synthesis and novel delivery is crucial.